Clinical trial NCT05193929: A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
Official title: A Multi-center, Randomized Controlled Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Diabetic Foot Ulcer
Lead sponsor: Compedica Inc
Sponsor class: INDUSTRY
Collaborators: name: Professional Education and Research Institute
First posted: 2022-01-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use.


Eligibility criteria: Inclusion Criteria:

1. At least 18 years old, inclusive.
2. Presence of a DFU, Wagner Grade 1 (see Appendix A for definitions) on the plantar or dorsal aspect of the foot, extending through the dermis provided it is below the medial aspect of the malleolus.
3. The index ulcer will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
4. Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
5. Index ulcer is a minimum of 0.8 cm2 and a maximum of 25 cm2 at SV1 and TV1.
6. Within 3 months of SV1, adequate circulation to the affected foot, as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable.
7. The target ulcer has been offloaded for at least 14 days prior to randomization.
8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed.

Exclusion Criteria:

* 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.

  2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.

  3. Index ulcer is overtly infected (i.e. purulent drainage). 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.

  5. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1.

  6. History of radiation at the ulcer site (regardless of time since last radiation treatment).

  7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies.

  8. Subjects with a previous diagnosis of HIV or Hepatitis C. 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.

  10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).

  11. Subject is pregnant or breast-feeding. 12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days.

  13. Subjects with end-stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of randomization. 14. Presence of active Charcot Neuroarthropathy to the affected limb. 15. Any wound located entirely on the medial or lateral border of the foot. 16. Any wound located between the 1st through 4th toe interspaces. 17. Index ulcer has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit.

Primary outcomes:
measure: Percentage of index ulcers healed
timeFrame: 12 weeks
Secondary outcomes:
measure: Time to Ulcer Healing
timeFrame: 12 weeks
measure: Percentage Area Change
timeFrame: 6 and 12 weeks
measure: Changes in wound quality of life from screening visit to end of study ( per W-QoL)
timeFrame: 12 weeks
Other outcomes:
measure: Cost to Closure
timeFrame: 12 weeks
Locations:
city: Phoenix
country: United States
facility: Titan Clinical Research
state: Arizona
city: Los Angeles
country: United States
facility: Felix Sigal
state: California
city: Los Angeles
country: United States
facility: Clemente Clinical Research
state: California
city: Vista
country: United States
facility: ILD Research
state: California
city: DeLand
country: United States
facility: Midland Florida clinical Research Center LLC
state: Florida
city: Homestead
country: United States
facility: Integral Clinical Trial Solutions
state: Florida
city: Pembroke Pines
country: United States
facility: Integral Clinical Trials Solutions
state: Florida
city: Tamarac
country: United States
facility: Integral Clinical Trials Solutions
state: Florida
city: Las Vegas
country: United States
facility: Viable Research Management
state: Nevada
city: New York
country: United States
facility: Foot Associates of New York
state: New York
city: Gastonia
country: United States
facility: Foot & Ankle specialists of the Mid-Atlantic
state: North Carolina
city: Raleigh
country: United States
facility: Foot & Ankle Specialists of the Mid-Atlantic
state: North Carolina
city: Boardman
country: United States
facility: Lower Extremity Institution of Research and Therapy (LEIRT)
state: Ohio
city: Houston
country: United States
facility: Mt. Olympus Medical Research
state: Texas
city: Houston
country: United States
facility: Clinical Trials Network
state: Texas
city: Roanoke
country: United States
facility: Foot and Ankle Specialist of the Mid-Atlantic - Roanoke
state: Virginia
city: Salem
country: United States
facility: Foot and Ankle Specialist of the Mid-Atlantic - Salem
state: Virginia
city: Salem
country: United States
facility: Salem Research institute
state: Virginia
city: Toronto
country: Canada
facility: East Toronto Vascular Clinic
state: Ontario
Study officials:
References: